US EditionKelun-Biotech Announces Approximately US$250 Million Placement
- On June 5th, 2025, Kelun-Biotech, a biopharmaceutical company based in Sichuan, issued 5,918,000 H shares on the Hong Kong stock exchange under its general mandate.
- The placement followed an upsized target from US$200 million to US$250 million due to strong demand from investors including sovereign wealth and healthcare specialist funds.
- The shares priced at HK$331.8 each, representing a 7.58% discount to the last close and a 0.89% premium to the five-day average, were multiple times oversubscribed.
- Kelun-Biotech's CEO, Dr. Michael Ge, expressed satisfaction with the ongoing backing from their major current shareholders, as well as the involvement of prominent new investors.
- Kelun-Biotech plans to use the approximately US$250 million net proceeds to advance research, clinical trials, and global drug development efforts.
Insights by Ground AI
Does this summary seem wrong?
61 Articles
61 Articles
All
Left
8
Center
22
Right
5
Rutland Herald+59 Reposted by 59 other sources
Kelun-Biotech Announces Approximately US$250 Million Placement
CHENGDU, China, June 5, 2025 /PRNewswire/ -- On June 5, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced the placement of 5,918,000 H shares under its general mandate, representing approximately 2.54% of the enlarged share capital…
Kelun's $250M PIPE; Valneva moves chikungunya vaccine to Phase 3 for kids
Plus, news about Trevi Therapeutics: Kelun Biotech’s $250M stock sale: The Sichuan company upsized its PIPE from $200 to $250 million and included investors from around the globe, including sovereign wealth funds and healthcare specialist ...
Coverage Details
Total News Sources61
Leaning Left8Leaning Right5Center22Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
63% Center
L 23%
C 63%
14%
Factuality
To view factuality data please Upgrade to Premium
